MX2021000290A - Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente dirigidos a ccr4. - Google Patents

Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente dirigidos a ccr4.

Info

Publication number
MX2021000290A
MX2021000290A MX2021000290A MX2021000290A MX2021000290A MX 2021000290 A MX2021000290 A MX 2021000290A MX 2021000290 A MX2021000290 A MX 2021000290A MX 2021000290 A MX2021000290 A MX 2021000290A MX 2021000290 A MX2021000290 A MX 2021000290A
Authority
MX
Mexico
Prior art keywords
ccr4
binding domain
engineered
compositions
antigen binding
Prior art date
Application number
MX2021000290A
Other languages
English (en)
Spanish (es)
Inventor
Jonathan C Lansing
Daniel Ortiz
Anthony Manning
Laura Rutitzky
Elma Kurtagic
Original Assignee
Momenta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Momenta Pharmaceuticals Inc filed Critical Momenta Pharmaceuticals Inc
Publication of MX2021000290A publication Critical patent/MX2021000290A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
MX2021000290A 2018-07-11 2019-07-11 Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente dirigidos a ccr4. MX2021000290A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862696746P 2018-07-11 2018-07-11
PCT/US2019/041324 WO2020014429A2 (en) 2018-07-11 2019-07-11 Compositions and methods related to engineered fc-antigen binding domain constructs targeted to ccr4

Publications (1)

Publication Number Publication Date
MX2021000290A true MX2021000290A (es) 2021-09-08

Family

ID=69142497

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021000290A MX2021000290A (es) 2018-07-11 2019-07-11 Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente dirigidos a ccr4.

Country Status (11)

Country Link
US (1) US20250346676A1 (cg-RX-API-DMAC7.html)
EP (1) EP3820517A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021531756A (cg-RX-API-DMAC7.html)
KR (1) KR20210042324A (cg-RX-API-DMAC7.html)
CN (1) CN113164590A (cg-RX-API-DMAC7.html)
AU (1) AU2019302662A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021000391A2 (cg-RX-API-DMAC7.html)
CA (1) CA3105985A1 (cg-RX-API-DMAC7.html)
IL (1) IL279987A (cg-RX-API-DMAC7.html)
MX (1) MX2021000290A (cg-RX-API-DMAC7.html)
WO (1) WO2020014429A2 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250084169A1 (en) 2022-01-12 2025-03-13 Biomolecular Holdings Llc Nk/monocyte engagers
CN119233997A (zh) * 2022-01-12 2024-12-31 生物分子控股有限责任公司 四面体抗体
CN121100128A (zh) * 2023-04-24 2025-12-09 百图生科(苏州)智能科技有限公司 异源多聚体多肽

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6488930B1 (en) * 1999-01-15 2002-12-03 Millennium Pharmaceuticals, Inc. Anti-CCR4 antibodies and methods of use therefor
US20050287138A1 (en) * 2003-10-08 2005-12-29 Kyowa Hakko Kogyo Co., Ltd. CCR4-specific antibody composition
US20090304715A1 (en) * 2006-03-03 2009-12-10 Tokyo University Of Science Modified antibodies with enhanced biological activities
WO2009086514A1 (en) * 2007-12-28 2009-07-09 Dana-Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
CN102549016B (zh) * 2009-06-30 2015-05-06 研究发展基金会 免疫球蛋白fc多肽
AU2013256010B2 (en) * 2012-05-04 2018-01-04 Dana-Farber Cancer Institute, Inc. Affinity matured anti-CCR4 humanized monoclonal antibodies and methods of use
US12391759B2 (en) * 2016-03-02 2025-08-19 Momenta Pharmaceuticals, Inc. Methods related to engineered Fc constructs
IL309293A (en) * 2016-05-23 2024-02-01 Momenta Pharmaceuticals Inc Compositions and methods relating to engineered FC constructs

Also Published As

Publication number Publication date
AU2019302662A1 (en) 2021-02-25
CA3105985A1 (en) 2020-01-16
JP2021531756A (ja) 2021-11-25
KR20210042324A (ko) 2021-04-19
IL279987A (en) 2021-03-01
EP3820517A2 (en) 2021-05-19
CN113164590A (zh) 2021-07-23
EP3820517A4 (en) 2022-04-06
WO2020014429A3 (en) 2020-02-13
US20250346676A1 (en) 2025-11-13
WO2020014429A2 (en) 2020-01-16
BR112021000391A2 (pt) 2021-04-06

Similar Documents

Publication Publication Date Title
EP3897623C0 (en) AMINO ACID ANILIDES AS SMALL MOLECULE MODULATORS OF IL-17
MX2021000307A (es) Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc dirigidos a cd38 diseñados por ingeniería genética.
MX2024013970A (es) Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos
CL2018003290A1 (es) Amidas heterocíclicas útiles como moduladores de proteínas (divisional de solicitud cl 2850-2018).
WO2020014413A3 (en) Compositions and methods related to engineered fc-antigen binding domain constructs targeted to ctla-4
AU2018256540A1 (en) Novel asphalt binder additive compositions and methods of use
MX383614B (es) Proteinas de union triespecificas y metodos de uso.
EA201991598A1 (ru) СОЕДИНЕНИЯ, МОДУЛИРУЮЩИЕ АРИЛУГЛЕВОДОРОДНЫЙ РЕЦЕПТОР (AhR)
MX2019000548A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostericos de shp2.
DK3464472T3 (da) Bitumensammensætning omfattende en voksblanding bestående af en råolievoks og en Fischer-Tropsch-voks, anvendelse af voksblandingen i bitumensammensætninger, anvendelse af bitumensammensætningen i asfaltsammensætninger, (...)
MX384363B (es) Nuevos polipéptidos de unión específica y usos de los mismos.
MX369486B (es) Diacuerpos enlazados covalentemente que tienen inmunoreactividad con pd-1 y lag-3, y métodos de uso de los mismos.
AR078516A1 (es) Moleculas de union a dll-4 (ligando 4 de tipo delta)
ES2571585T3 (es) Adhesivo termofusible a base de un copolímero de impacto de polipropileno
CO2018005315A2 (es) Moduladores de la interacción de sestrina-gator2 y sus usos
DK3768284T3 (da) Sammensætninger af enterococcus flagellin til anvendelse i terapi
ATE399190T1 (de) Zusammensetzungen von monomeren fluortensiden
MX2021000287A (es) Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente.
BR112021021048A2 (pt) Polipeptídeos que se ligam a cd33 e seus usos
MX2021000281A (es) Composiciones y métodos relacionados con construcciones de dominio de unión a antígeno y fc modificadas genéticamente dirigidas a pd-l1.
WO2020014429A3 (en) Compositions and methods related to engineered fc-antigen binding domain constructs targeted to ccr4
BR112018071592A2 (pt) inibidores de erbb e usos dos mesmos
EP3713644C0 (en) COMPOSITIONS AND METHODS FOR MODULATING HIF-2A TO ENHANCE MUSCLE PRODUCTION AND REPAIR
MX2018003445A (es) Expresion de proteinas que contienen fc.
MX2021000280A (es) Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente.